



press release

Press release

For immediate release

ZOOMMED ANNOUNCES A FIRST CLOSING FOR THE PRIVATE PLACEMENT ANNOUNCED APRIL 27, 2010

Montreal, May 6, 2010 - ZoomMed Inc. (TSX Venture Exchange: ZMD), creator of the **ZRx Prescriber**, the **e-Pic communication network** and the **ZRx Pharma communication network** announces a first closing of the offering previously announced on April 27, 2010, for gross proceeds of \$2,000,000, the minimum amount to be raised in connection with this private placement. As part of this first closing, 10,000,000 shares of **ZoomMed** were issued at a price of \$0.20 per share.

The final closing of this private placement has to be completed within forty-five (45) days of the initial announcement made by **ZoomMed** on April 27, 2010, which is on or before June 11, 2010.

ZoomMed announced its intention to raise a minimum of \$2,000,000 up to a maximum of \$2,700,000 through a non-brokered private placement of units. Each unit, priced at \$0.20, is comprised of one common share of **ZoomMed**. A minimum of 10,000,000 and a maximum of 13,500,000 common shares of **ZoomMed** may be issued under this private placement.

Use of proceeds will be used to develop new services, which are more and more requested, and marketing activities in order to increase revenues and Cash Flows.

About the ZRx Prescriber

ZoomMed developed the **ZRx Prescriber**, a technologically innovative Web application that enables physicians to use a wireless device, such as the iPod Touch™, iPhone™, other PDA's or computers, to rapidly write and deliver scripts. The **ZRx Prescriber** is quick, efficient and intuitive. Since it is a stand-alone product, it can easily be integrated to any Electronic Medical Record application (EMR).

About the e-Pic communication network

ZoomMed's e-Pic communication network allows intercommunications between physicians who use the **ZRx Prescriber** and pharmacists who are members of the network. Thus, physicians and pharmacists can transfer, capture (scan), and electronically receive prescription information and prescription renewal information through this high speed and entirely secure network.

About the ZRx Pharma communication network

ZRx Pharma communication network, the new revolutionary communication tool, allows information dissemination and intercommunication between pharmaceutical corporations and physicians using the **ZRx Prescriber**, such as; continuing medical education, new product launches, medical training, major medical alerts, clinical studies and surveys.

Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond ZoomMed's control. Such risks include but are not limited to: the impact of general economic conditions, changes in the regulatory environment in the jurisdictions in which ZoomMed does business, stock markets volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, as well as other risks disclosed in public filings of ZoomMed. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and ZoomMed is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise.

For further information on ZoomMed, contact Mr. Yves Marmet, President and Chief Executive Officer (450) 678-5457, Ext 228, info@zoommed.com or visit our Web Site; www.zoommed.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release